Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Identification of Risk Factors for Myeloma Progression in African American Patients

David E. Mery, Yihao Zhan, Hongling Peng, Eric Siegel, Cody Ashby, Clyde Bailey, Catherine Ma, Hongwei Xu, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2024) 144 (Supplement 1): 1937.

https://doi.org/10.1182/blood-2024-212173

Published: 2024

Journal Articles

Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)

Sharmilan Thanendrarajan, Phil Farmer, Clyde Bailey, Carolina Schinke, Samer Al Hadidi, Maurizio Zangari, Stephanie Rogers, Anne Williams, Fenghuang Zhan, John D Shaughnessy, Jr, Tanvi H. Patel, Anup Kumar Trikannad, Asis Shrestha, Syed Naqvi, Hira Imad Cheema, Trilok Shrivastava, Manozna Karri, Ramya Bachu, Frits van Rhee

Blood (2024) 144 (Supplement 1): 4713.

https://doi.org/10.1182/blood-2024-206152

Published: 2024

Journal Articles

Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression

Catherine Ma, Fumou Sun, Clyde Bailey, Hongwei Xu, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2024) 144 (Supplement 1): 4676.

https://doi.org/10.1182/blood-2024-204135

Published: 2024

Journal Articles

The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans

Yihao Zhan, Hongling Peng, David E. Mery, Eric Siegel, Clyde Bailey, Catherine Ma, Hongwei Xu, Daisy V. Alapat, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2024) 144 (Supplement 1): 1904.

https://doi.org/10.1182/blood-2024-203848

Published: 2024

Journal Articles

Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages

Blood (2024) 144 (Supplement 1): 4729.

https://doi.org/10.1182/blood-2024-193583

Published: 2024

Journal Articles

Global Proteomics Identifies CDK11A/B As Integral to Myeloma Proliferation and High-Risk Disease

David E. Mery, Visanu Wanchai, Cody Ashby, Hongwei Xu, Eric Siegel, Clyde Bailey, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2023) 142 (Supplement 1): 1932.

https://doi.org/10.1182/blood-2023-187592

Published: 2023

Journal Articles

Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma

Samer Al Hadidi, Obada Ababneh, Carson W Ercanbrack, Carolina Schinke, Sharmilan Thanendrarajan, Clyde Bailey, Robert Smith, Susan Panozzo, Guido Tricot, Daisy V. Alapat, John D Shaughnessy, Jr, Fenghuang Zhan, Bart Barlogie, Maurizio Zangari, Frits van Rhee

Blood (2023) 142 (Supplement 1): 3594.

https://doi.org/10.1182/blood-2023-181034

Published: 2023

Journal Articles

Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma

Carolina Schinke, Leo Rasche, Cody Ashby, Rudy van Hemert, Sharmilan Thanendrarajan, Samer Al Hadidi, Maurizio Zangari, Clyde Bailey, Daisy V. Alapat, John D Shaughnessy, Jr, Fenghuang Zhan, Bart Barlogie, Frits van Rhee, Niels Weinhold

Blood (2023) 142 (Supplement 1): 882.

https://doi.org/10.1182/blood-2023-180896

Published: 2023

Journal Articles

A 5-Stage System for ASCT Multiple Myeloma

Wancheng Guo, David E. Mery, Eric Siegel, Fumou Sun, Yan Cheng, Visanu Wanchai, Cody Ashby, Clyde Bailey, Daisy V. Alapat, Hongling Peng, Samer Al Hadidi, Sharmilan Thanendrarajan, Carolina Schinke, Maurizio Zangari, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2023) 142 (Supplement 1): 3331.

https://doi.org/10.1182/blood-2023-181117

Published: 2023

Journal Articles

A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance

Blood (2022) 140 (Supplement 1): 264–265.

https://doi.org/10.1182/blood-2022-163654

Published: 2022

Journal Articles

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant

Nishanth Thalambedu, Yetunde Ogunsesan, Jaskirat Sethi, Munawwar Hussain, Lakshmi Yarlagadda, Sravani Gundarlapalli, Horace J. Spencer, Clyde Bailey, Samer Al Hadidi, Sharmilan Thanendrarajan, Maurizio Zangari, John D. Shaughnessy, Jr., Fenghuang Zhan, Juan Carlos Rico Crescencio, Frits van Rhee, Carolina Schinke

Blood (2022) 140 (Supplement 1): 12922–12923.

https://doi.org/10.1182/blood-2022-169353

Published: 2022

Journal Articles

Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

Yetunde Ogunsesan, Reid D. Landes, Jaskirat Sethi, Munawwar Hussain, Nishanth Thalambedu, Lakshmi Yarlagadda, Sravani Gundarlapalli, Clyde Bailey, Samer Al Hadidi, Sharmilan Thanendrarajan, Maurizio Zangari, John D. Shaughnessy, Jr., Fenghuang Zhan, Frits van Rhee, Carolina Schinke

Blood (2022) 140 (Supplement 1): 10579–10580.

https://doi.org/10.1182/blood-2022-167624

Published: 2022

Journal Articles

Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission

Kristin Larsen, Meera Mohan, MD, Clyde Bailey, Kerri Hill, Horace Spencer, Mathew Kottarathara, MD, Richa Parikh, MD, Shadiqul Hoque, MD, Amani Erra, MD, Angel Mitma, MD, Pankaj Mathur, MD, Guido Tricot, MD PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, Carolina D. Schinke, MD

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-142527

Published: 2020

Journal Articles

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

Frits van Rhee, MD PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Jeffery R. Sawyer, Adam Rosenthal, MS, Doug Steward, Phil Farmer, Robert Smith, Milan Bimali, PhD, Mariam M. Boota, MD, Clyde Bailey, Brian A Walker, PhD, Antje Hoering, PhD, Gareth Morgan, MD PhD, Maurizio Zangari, MD, Faith E. Davies, MD

Blood (2019) 134 (Supplement_1): 4569.

https://doi.org/10.1182/blood-2019-131887

Published: 2019

Journal Articles

An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome

Jeffery R. Sawyer, Erming Tian, PhD MBA, Brian A Walker, PhD, Christopher P. Wardell, PhD MSc, BSc, Joshua Epstein, DSc, Janet L Lukacs, Gael M. Sammartino, Clyde Bailey, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Faith E. Davies, MD, Frits van Rhee, MD PhD, Gareth Morgan, MD

Blood (2018) 132 (Supplement 1): 4489.

https://doi.org/10.1182/blood-2018-99-115090

Published: 2018

Journal Articles

Chromosome 1q12 Instability Drives Both 1q21 Amplification and Arm-Length Deletions in Multiple Myeloma

Jeffery R. Sawyer, Erming Tian, PhD MBA, Brian A Walker, PhD, Charles M. Swanson, Janet L Lukacs, Gael M. Sammartino, Clyde Bailey, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD

Blood (2017) 130 (Supplement 1): 3060.

https://doi.org/10.1182/blood.V130.Suppl_1.3060.3060

Published: 2017

Journal Articles

Outcomes of Autologous Transplantation for Treatment-Related AML and MDS in Previously Treated Multiple Myeloma Patients (pts)

Shebli Atrash, Bart Barlogie, MD PhD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Sarah Waheed, MD, Clyde Bailey, Nathan Petty, MS, Christoph Heuck, MD, Gareth J Morgan, MDPhD, Yogesh Jethava, MD

Blood (2015) 126 (23): 1997.

https://doi.org/10.1182/blood.V126.23.1997.1997

Published: 2015

Journal Articles

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

Blood (2015) 126 (23): 3181.

https://doi.org/10.1182/blood.V126.23.3181.3181

Published: 2015

Journal Articles

Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Xenofon Papanikolaou, MD, Rashid Z Khan, MD, Adam Rosenthal, Clyde Bailey, Yogesh Jethava, MB, MRCP, MD FRCPath, Christoph Heuck, MD, Susan B. Panozzo, BS, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Carolina Schinke, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2128.

https://doi.org/10.1182/blood.V124.21.2128.2128

Published: 2014

Journal Articles

Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma

Christoph Heuck, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Rashid Z Khan, MD, Scott Miller, Alan Mitchell, Donald Johann, MD MS, Kelly Robbins, Ryan K Van Laar, PhD, Siraj Ali, MDPhD, Vincent A. Miller, MD, Clyde Bailey, Jeffery Sawyer, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD, PhD

Blood (2014) 124 (21): 4775.

https://doi.org/10.1182/blood.V124.21.4775.4775

Published: 2014

NARROW

Identification of Risk Factors for Myeloma Progression in African American Patients

Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)

Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression

The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans

Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages

Global Proteomics Identifies CDK11A/B As Integral to Myeloma Proliferation and High-Risk Disease

Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma

Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma

A 5-Stage System for ASCT Multiple Myeloma

A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant

Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome

Chromosome 1q12 Instability Drives Both 1q21 Amplification and Arm-Length Deletions in Multiple Myeloma

Outcomes of Autologous Transplantation for Treatment-Related AML and MDS in Previously Treated Multiple Myeloma Patients (pts)

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only